Shanghai-based Excalipoint Therapeutics launched with an oversubscribed $68.7 million seed financing, including a $41 million initial round in August 2025 and a $27.7 million extension.1234
The funding supports proprietary platforms like TOPAbody, T-Cell Immune Shield, and TCE Probody, plus a pipeline of six T-cell engager programs for cancer (e.g., DLL3-targeting EXP011 in Phase I/II) and autoimmune diseases.2345
Investors include Hongshan Capital (HSG), Apricot Capital, Yuanbio Venture Capital, MPCi, Centurium Capital, Lilly Asia Ventures, and Eisai Innovation Fund; one of the largest seed rounds for a Chinese biotech.234
Founders leverage China's efficient clinical development and large patient access to rapidly advance therapies, with CEO Lei Fang emphasizing global competitiveness.345
Lead programs licensed from Lepu Biopharma target solid tumors like colorectal, gastric, pancreatic, and DLL3-expressing malignancies.2
Sources:
1. https://www.thepharmaletter.com/biotech-news/excalipoint-therapeutics-launches-with-68-7-million
2. https://www.biopharmadive.com/news/excalipoint-biotech-startup-china-t-cell-engagers/814829/
3. https://www.bioxconomy.com/investment/excalipoint-secures-68-7m-to-advance-t-cell-engager-platforms
4. https://www.businesswire.com/news/home/20260318260662/en/Excalipoint-Therapeutics-Launches-with-$68.7-Million-to-Develop-Next-Generation-T-Cell-Engager-Therapies
5. https://www.biospace.com/business/lilly-backed-china-startup-debuts-with-68-7m-seed-to-advance-next-gen-t-cell-engagers